Establishment of ZENOAQ HOLDINGS CO., LTD.
The veterinary pharmaceutical company Nippon Zenyaku Kogyo Co., LTD., and the human pharmaceutical company ZENOAQ Resource Co., LTD. (now ZENOGEN Pharma Co., LTD.) became wholly owned subsidiaries of ZENOAQ HOLDINGS CO., LTD.
Appointment as a Corporate Member of HealthforAnimals.
Establishment of the New York Branch Office in the U.S.A.
Appointment of Mr. Toshikazu Fukui as President.
Winner of the Fukushima Industry Award 2017.
Completion of the construction of the new quality control center in Koriyama, Japan.
Winner of the Japan Quality Award 2016.
Establishment of Vetoquinol-Zenoaq K.K., a joint venture with Vetoquinol SA.
Research and development collaboration with Nexvet.
Winner of the Animal Pharm Award 2014 for Best Company in Asia/Australasia.
Completion of the construction of the state-of-the-art, GMP-compliant biological manufacturing plant (Third Manufacturing Plant) in Koriyama, Japan.
Completion of the construction of the new main administration building, a symbol of recovery in Koriyama, Japan, from the Great East Japan Earthquake of 2011. The building is an eco-friendly, open office building that uses natural energy.
Establishment of the Tokyo Branch Office.
Severe damage caused to ZENOAQ's head office in Koriyama by the Great East Japan Earthquake. The beginning of the road to recovery.
Acquisition of Nippon Biologicals Inc., a company that develops and imports avian vaccines as an affiliate.
Appointment of Dr. Kuniaki Fukui, former President of Nippon Zenyaku Kogyo Co., Ltd,
Appointment of Mr. Keiichi Takano to Dr. Fukui's previous role as President.
April, May, December 2008
Completion of the construction of new buildings of the Central Research Laboratory Animal Research Center in Koriyama, Japan.
Business tie-up with IDEXX Laboratories K.K.
Establishment of the Beijing Representative Office in China to target the Chinese and Korean markets.
Business tie-up with Nippon Biologicals, Inc.
Business tie-up with Zinpro Animal Nutrition Japan K.K.
Commencement of import and sales of mineral salt blocks manufactured at Tianjin Zenyaku Animal Health Co., Ltd in China.
Announcement of the corporate brand, ZENOAQ.
Integration of the head office and 6 marketing subsidiaries throughout Japan as
Nippon Zenyaku Kogyo Co., Ltd.
Set-up of sales system according to animal groups (Dairy Cattle, Beef Cattle, Swine, Avian and Companion Animal).
Set-up of Tianjin Zenyaku Animal Health Co., Ltd. as a manufacturing plant in China.
Merging of Merial Nippon Zenyaku Limited with Merial Japan Limited.
Nippon Zenyaku Kogyo undertakes a portion of the equity.
Creation of the Avian Business Division.
Celebration of the 50th year anniversary of Nippon Zenyaku Kogyo.
Establishment of Rhone-Merieux Nippon Zenyaku Limited, a joint venture with Rhone Merieux (later changed to Merial Nippon Zenyaku Limited).
Establishment of the Clinical Research Farm in Ono. This facility, together with the Central Research Laboratory, is GLP-compliant.
Appointment of Mr. Kuniaki Fukui as President.
Establishment of Kobayashi manufacturing plant in Kyushu, where the livestock
industry had suddenly expanded.
The new plant focused on the production of KOEN®.
Establishment of the Central Research Laboratory and a laboratory for specialized experiments involving large animals. The laboratory was completed on a scale never before seen by animal pharmaceutical makers of the time in Japan.
Business tie-up with Fujisawa Pharmaceutical Co., Ltd.
Completion of the construction of the new manufacturing plant in Koriyama (Asaka), Japan.
Business tie-up with SmithKline and French Laboratories (SK&F). This was ZENOAQ's first business partnership with an overseas company. This began the importation and sale of SK&F's products, including vaccines and heartworm medications.
Establishment of the Kushiro manufacturing plant in Hokkaido, the region with the
largest demand for mineral salts.
Following a sudden increase in livestock populations in Hokkaido, the decision was made to expand production to meet future demand. As the necessity of salt and minerals became more widely recognized, new products, such as KOEN® M and KOEN® S, were launched.
Establishment of the Hokkaido Shakunage Forum. In order to realize the company motto of being a company indispensable to the livestock industry, the Hokkaido Shakunage Forum, focused on uniting industry, government, and academia, was established. Following this inaugural event, shakunage forums were set up in Kanto, Kyushu, and more, spreading nationwide.
Commencement of manufacturing of vial products.
Establishment of a manufacturing plant for mineral salt blocks known as KOEN®.
Establishment of an additional plant in Koriyama (Showa), Japan.
Commencement of manufacturing of antibiotic formulations.
The PR video "Cow-Targeting Parasites" was produced and released to promote the spread of new pharmaceuticals nationwide.
Successful R&D of Neo Hexaron, a liver fluke parasiticide in Sadogashima.
Company name changed to Nippon Zenyaku Kogyo Co., Ltd.
Commencement of the manufacturing of veterinary pharmaceuticals following acceptance of
an order from Fukushima Prefecture.
After receiving an order for Ringer's solution for horses, the company began production of osteomalacia pharmaceuticals, including OSM and OSM Strong.
Establishment of Asahi Yakuhin Kogyo Co., Ltd, which would later be renamed Nippon
Zenyaku Kogyo Co., LTD., a human pharmaceutical manufacturing company with a capital
of 180,000 yen.
Commencement of manufacturing in Koriyama (Miyata), Japan.